Christine Gonzales, MD
Ophthalmology · Ashland, ORNPI 1700809365
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,736 of the $2,511 with a category attached, or 69.2%. 10 manufacturers reported payments, led by AbbVie at 41.9% of the total. Reporting peaked in 2020 at $1,063 and has fallen 70.4% since, to $315 in 2025.
Across 38 payments — averaging $66.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$817
- Genentech USA, Inc.$196
- Bausch & Lomb, A Division Of Bausch Health US, LLC$184
- Astellas Pharma US Inc$83
- ANI Pharmaceuticals, Inc.$50
- plus $129 from 4 others
Across 11 payments — averaging $1943.92 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$9K
- Aerie Pharmaceuticals, Inc.$6K
- Astellas Pharma Global Development$6K
- AbbVie$800
What the payments were for
- Consulting fees$75030%
- Food & beverage$1,73669%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 10 | $1,051 |
| Regeneron Healthcare Solutions, Inc. | 9 | $817 |
| Genentech USA, Inc. | 6 | $196 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $184 |
| Astellas Pharma US Inc | 3 | $83 |
| ANI Pharmaceuticals, Inc. | 2 | $50 |
| Novartis | 3 | $46 |
| Bausch & Lomb Americas Inc. | 1 | $43 |
| Amgen | 1 | $24 |
| Alimera Sciences, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- EYLEA HD$472
- OZURDEX$129
- STELLARIS PC$109
- VABYSMO$101
How this compares
$2,511 in reported general payments places this provider in the 75th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 95 | $3,894 |
| Ketorolac Tromethamine | 50 | $1,049 |
| Latanoprost | 42 | $626 |
| Dorzolamide Hcl | 37 | $605 |
| Timolol Maleate | 58 | $554 |
| Brimonidine Tartrate | 25 | $246 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Ashland
- Jeffrey WelderAshland$4K
- David HuangCorvallis$67K
- Mark PennesiPortland$56K
- Rene ChoiPortland$21K
- Balamurali AmbatiEugene$19K
- Richard HoffmanEugene$17K
- Bart AdamsPendleton$17K
- Richard WeleberPortland$14K
- Aazim SiddiquiPortland$13K
- Kurt AndreasonBend$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.